NEW YORK (GenomeWeb) – Noninvasive prenatal screening for chromosomal aneuploidies from cell-free DNA in the mother's blood has been taking off in recent years, and recent studies have shown that it performs well in both high-risk and average-risk pregnancies.

During a panel discussion at Cambridge Healthtech Institute's Advances in Prenatal Molecular Diagnostics conference in Boston earlier this month, representatives from four NIPT providers – Ariosa Diagnostics, Natera, Sequenom, and Illumina − shared their vision for their own tests and the future of NIPT.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.